Výsledky vyhledávání - "Vito J Palombella"

Akademický článek

The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a

Autor: Li Zhang, Emmanuel Normant, Ammar Adam, Marisa O Peluso, Caroline M Armet, Rachel W O’Connor, Benjamin H Lee, Andrew C Lake, Scott C Chappel, Jonathan A Hill, Vito J Palombella, Pamela M Holland, Alison M Paterson

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Background CD47 is a broadly expressed cell surface glycoprotein associated with immune evasion. Interaction with the inhibitory receptor signal regulatory protein alpha (SIRPα), primarily expressed on myeloid cells, normally serves to restrict effe

Externí odkaz: https://doaj.org/article/5c5412f6b8c54e9fb65a54d23faabf2e

Zobrazit plný text záznamu

Akademický článek

HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.

Autor: Brenda C O'Connell, Katie O'Callaghan, Bonnie Tillotson, Mark Douglas, Nafeeza Hafeez, Kip A West, Howard Stern, Janid A Ali, Paul Changelian, Christian C Fritz, Vito J Palombella, Karen McGovern, Jeffery L Kutok

Publikováno v: PLoS ONE, Vol 9, Iss 12, p e115228 (2014)

HSP90 inhibitors are currently undergoing clinical evaluation in combination with antimitotic drugs in non-small cell lung cancer (NSCLC), but little is known about the cellular effects of this novel drug combination. Therefore, we investigated the m

Externí odkaz: https://doaj.org/article/9d093119cf444dc3945b927b8fef1652

Zobrazit plný text záznamu

SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties

Publikováno v: ImmunoHorizons. 7:366-379

CD39 (ENTPD1) is a key enzyme responsible for degradation of extracellular ATP and is upregulated in the tumor microenvironment (TME). Extracellular ATP accumulates in the TME from tissue damage and immunogenic cell death, potentially initiating proi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::730fecc8a4a2e77108479d6425a15698
https://doi.org/10.4049/immunohorizons.2200089

Zobrazit plný text záznamu

Abstract 5125: Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu

Autor: Marisella Panduro, Yue Ren, Ricard Masia, Yu Yang, Andrew C. Lake, Vito J. Palombella, Jonathan A. Hill, James F. Mohan

Publikováno v: Cancer Research. 83:5125-5125

FOXP3+ regulatory T (Treg) cells play a crucial role in orchestrating immune responses across several tissues, including the tumor microenvironment (TME). The dominant immune regulatory activity of Treg cells is evidenced, both clinically and preclin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2830d10e0d4ff045fe2ab895f56e6f08
https://doi.org/10.1158/1538-7445.am2023-5125

Zobrazit plný text záznamu

726 SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC

Autor: Andrew Lake, Christopher Converse Wells, Bijan Etemad-Gilbertson, Austin Dulak, Das Sonia, Vito J. Palombella, Warren Michael, Ernest S. Smith, Pamela M. Holland, Maria Scrivens

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background T regulatory cells (Tregs) are potent suppressors of immune activation in the periphery and tumor microenvironment (TME). Tumor-infiltrating Tregs have also been associated with resistance to cancer therapies. Loss of peripheral Tregs can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ad6a2fd11e9e1957d3d60cde95fef4b
https://doaj.org/article/ed7f6d75d4c8448fa6d8083af15bf784

Zobrazit plný text záznamu

727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors

Autor: Jonathan A. Hill, Marisa O. Peluso, Pamela M. Holland, Isabelle Cousineau, Ricard Masia, Benjamin H. Lee, Matthew Rausch, John Stagg, Jing Hua, Secil Koseoglu, Simon Turcotte, Vito J. Palombella, Gege Tan, Devapregasan Moodley

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background IL-27 is a heterodimeric cytokine consisting of IL 27p28 and Epstein-Barr virus-induced gene 3 (EBI3) that binds the IL-27 receptor subunit alpha and glycoprotein 130. IL-27 is produced by activated macrophages and dendritic cells and limi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e244b47373a3f3b129a87376518fc85
https://doi.org/10.1136/jitc-2020-sitc2020.0727

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání